1 / 31

CML & MPDs Practitioner Conference CML: Cases and interactive voting

CML & MPDs Practitioner Conference CML: Cases and interactive voting. Brian Huntly University of Cambridge and Addenbrookes Hospital. Case 1. 37 year old male WCC 80, Plts 840, Baso 6%, Blasts 2%, no spleen BCR-ABL positive, Sokal/Hasford low-risk 3 siblings

shotwell
Télécharger la présentation

CML & MPDs Practitioner Conference CML: Cases and interactive voting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CML & MPDs Practitioner Conference CML: Cases and interactive voting Brian Huntly University of Cambridge and Addenbrookes Hospital

  2. Case 1 • 37 year old male • WCC 80, Plts 840, Baso 6%, Blasts 2%, no spleen • BCR-ABL positive, Sokal/Hasford low-risk • 3 siblings • Started on Nilotinib in ENEST trial, March 2011

  3. Case 1 • Patient entered CHR but problems with cytopenias • Further cytopenias (Gd III thrombocytopenia and neutropenia) required dose interruption • Early marrow 3 months of Nilotinib – Ph 40%, BCR-ABL:ABL ratio 43% • Tissue typing demonstrates a fully matched sib • What would you do now?

  4. Case 1 • Patient continued on Nilotinib • 2 further 3 week interruptions due to cytopenias • Repeat marrow at 6 months – 25% Ph positive, 31% BCR-ABL:ABL ratio 43% • What would you do now?

  5. Case 1 • Patient continued on Nilotinib • No further interruptions due to cytopenias • Repeat marrow at 12 months – 0/200 cells Ph positive, BCR-ABL:ABL ratio 0.1%

  6. Case 1 • Patient continued on Nilotinib • No further interruptions due to cytopenias • Repeat marrow at 12 months – 0/200 cells Ph positive, BCR-ABL:ABL ratio 0.1% • BUT – Karyotype shows 3 small separate clones - +6 8/200 +X 10/200 + 8 20/200 • NO evidence of dysplasia • What would you do now?

  7. Case 1 • Patient continued on Nilotinib • Repeat marrow at 18 months – ALL cells Ph-ve, ONLY + 8 18/200 cells • Foe repeat marrow at 2 years and ?beyond

  8. Significance of clonal abnormalities in Ph- clone following TKI? • Incidence of clonal cytogenetic abnormalities in Ph NEGATIVE clone (CCA/Ph-) following TKI Rx varies (range of 2-17% of patients in described series) • -7, -5, -Y and +8 most common • Significance unknown • Overall prognosis is good – one series of 515 patients – 30 CCA/Ph- patients with no difference in survival vs similar CCR patients (only 2/30 patients developed MDS median FU 51 months) • MD Anderson- 1701 evaluable patients, 21 with CCA/Ph-, 3 developed other haem malignancies – (1 AML and 2 MDS-> AML)

  9. Case 2 • Patient 2 - 36 year old female lawyer • Presented 2009 at 12 week booking – WCC 220, Plt 372, Spleen 3cm • Sokal/Hasford – Low • African ethnicity, 6 siblings • Patient decided on a TOP • Declined trial entry (SPIRIT 2, BELA) started Imatinib 400mg

  10. Case 2 • CHR at 3 months • 6 month marrow – 18% Ph positive, BCR-ABL:ABL ratio 21% • 1 year – 4% Ph pos, BCR-ABL:ABL ratio 9.7% • What would you do now?

  11. Case 2 • Patient reports that she is pregnant! • What would you do now?

  12. Management of pregnancy in patients with CML • Tyrosine kinase inhibitors are associated with adverse outcomes during pregnancy (180 pregnancies, 12 (7%) fetal abnormalities, 18 (10%) spontaneous abortions) • Of the 63 normal births in the series 18 (29%) received IM for the duration of the pregnancy • Risk of interrupting therapy to the patient - relates to degree of response seen before cessation (Kuwabara et al Blood 2010 – only 2/7 patients achieved ≥ MMR after reintroduction TKI, both had an optimal MMR response before stopping) • Options for control of disease: • α-IFN • Leucapheresis • Use of TKI in 3rd trimester?

  13. Case 2 • Imatinib stopped and patient discussed with fetal medicine – pregnancy monitored as high-risk • 18/40 loss of HR - α-IFN and dose titrated against SE, LMWH Rx instituted • MTD 3MU/3 x per week • 28/40, WCC 58 -Leucapheresis instituted weekly, total of 9 required • Scans all normal with no evidence of IUGR • Induced at 36 weeks in discussion with obstetricians

  14. Case 2 • Following delivery patient commenced upon Dasatinib, advised not to breast feed, WCC 43, BCR-ABL: ABL ratio 117% • CHR 3 weeks • 3 months BCR-ABL: ABL ratio 64% • 6 months BCR-ABL: ABL ratio 9.9% • 12 months BCR-ABL: ABL ratio 1.3%, mutation screen negative • 18 months BCR-ABL: ABL ratio 0.9% • What would you do now?

  15. Case 2 • Patient continues on Dasatinib • Tissue typed and early discussions re transplant

  16. Case 3 • Patient 3 28 y male diagnosis in 2005 • WCC 143, Spleen 12cm • Sokal/Hasford – Low • No siblings, caucasian background • Started IM 400mg

  17. Case 3 • CHR but not CCR(4% Ph+) after 1 year, BCR-ABL 2% • IM increased to 600mg and then 800mg (2005-2007) • Eventual CCR (~24/12), without MMolR, BCR-ABL: ABL ratio – 0.4-0.7% • Mutation screen negative • What would you do now?

  18. Case 3 • Patient changed to Dasatinib 100mg in May 2007 • No change in BCR-ABL: ABL ratio on 3/12 100mg • Dasatinib increased to 140mg • Slow but steady response over next next 2.5 years • Achieved MMolR in Feb 2010 – continues on Dasatinib 140mg in MMolR

  19. Case 3 • Heart murmur picked up coincidentally 2012 – No symptoms • Previous episode of palpitations 2008 – 24h Holter monitor and echo normal • Repeat echo 2012– flow murmur, normal LV and RV function but increased pulmonary artery pressure suggested • Confirmed by stressdoppler echo – Right heart catheterisation awaited • ? Pulmonary Arterial Hypertension • ? Dasatinib related • What would you do now?

  20. Case 3 • Reduction in dasatinib (100mg, possibly 50mg) with CML response and PAH monitoring • ?Other TKI –which • If PAH improves but molecular response worsens - ?Allo SCT

  21. Dasatinib and PAH – learning points • Reports from 2009 onwards • Incidence is not known – French registry 0.45% (Montani et al Circulation 2012) • Majority of patients are symptomatic (exertional dyspnoea) • Pre-capillary, mutation negative for inherited PAH, no other predisposition • Withdrawl, dose reduction are recommended • Reversible component upon cessation of Dasatinib – degree variable • Consider if DAS patients with exertional dyspnoea, no evidence of pleural effusion, pulmonary oedema, anaemia or lung infiltration • Registry for side-effects of TKI – Dragana Milojkovic Hammersmith ( d.milojkovic@imperial.ac.uk )

  22. Acknowledgements • Tessa Holyoake, Glasgow • Adam Meade, Oxford

More Related